Cocrystal, NIAID expand partnership for Covid-19 protease inhibitors
02 Jun 2022
Cocrystal is developing Covid-19 drug candidates that act on proteins linked to viral replication. Credit: Masum Ali from Pixabay.
Cocrystal Pharma has expanded a Non-Clinical Evaluation Agreement (NCEA) with the National Institutes of Health (NIH) unit National Institute of Allergy and Infectious DiseasesInfectious Diseases (NIAID) to carry out exploratory preclinical studies of the former’s 3CL protease inhibitors to treat Covid-19.
Under the NIAID partnership, Cocrystal offered its process chemistry knowledge for its oral 3CL protease inhibitors while the NIAID will provide support to augment the synthesis of a crucial intermediate of the inhibitors.
NIAID carries out and offers support for basic and applied research to better understand, treat and avert infectious, immunologic and allergic ailments.
Cocrystal is developing Covid-19 drug candidates that act on proteins linked to viral replication.
Related
Regardless of the different strains of the virus that may exist or evolve, these enzymes are needed for viral replication and are highly conserved across all strains.
The antiviral compounds of Cocrystal are designed to be effective against key strains of the virus by acting on these highly conserved regions of the replication enzymes.
The main SARS-CoV-2 protease inhibitorsSARS-CoV-2 protease inhibitors of the company were found to have potent in vitro pan-viral activity against common human coronaviruses, rhinoviruses and respiratory enteroviruses that usually cause the common cold, as well as against noroviruses that could cause symptoms of acute gastroenteritis.
Cocrystal Pharma president and co-interim CEO Sam Lee said: “We are pleased to expand our collaboration with NIAID to support our ongoing API synthesis of Cocrystal’s oral 3CL protease inhibitors.
“We are grateful to receive the NIAID’s additional support and look forward to further expanding our collaborative work going forward.”
In January this year, the company selected two investigational antiviral drug candidates, CDI-988 and CDI-873, to further develop them as oral therapies for Covid-19.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.